Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer

Anticancer Research

Volumn 16, Issue 4 C, 1996, Pages 2357-2364

  Whiteside, Theresa L ^a,b   Chikamatsu, Kazuaki ^b   Nagashima, Shigeki ^b   Okada, Kazuhiko ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Activated NK cells; Antitumor effector cells; Cytolytic T lymphocytes; Head and neck cancer; Immunotherapy

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; MOUTH CARCINOMA; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, NUDE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0029791272     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boring CC, Squires TS, Tong T: Cancer Statistics. Cancer J Clin 44: 7-26, 1994.
2. Cancer of the Head and Neck, Third Edition (Myers EN and Suen JY, eds). Philadelphia, W.B. Saunders Co., 1995.
3. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE and Steinberg SM: Prospective randomized trial of high-dose interleukin 2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI 85: 622-627, 1993.
4. Rosenberg SA, Yannelli JR, James CY, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhom JH and White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltring lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159-1166, 1994.
5. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, deKernion J and Figlin R: Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urology 150: 1384-1390, 1993.
6. Cortesina G, DeStefani A, Giovarelli M, et al: Treatment of recurrent squamous cell carcinoma of head and neck with low dose of interleukin-2 (IL2) injected perilymphatically. Cancer 62: 2482-2487, 1988.
7. Rivoltini L, Gambacorti-Passerini C, Squadrelli-Saraceno M et al: in vivo interleukin 2induced activation of lymphokine-activated killer cells and tumor cytotoxic T cells in 16 cervical lymph nodes of patients with head and neck tumors. Cancer Res 50: 5551-5557, 1990.
8. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB, Rubin J and Vlock DR: Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck: Cancer Res 53: 5654-5662, 1993.
9. Berke G: The binding and lysis of target cells by cytoloxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol. 12: 735-774, 1994.
10. Vujanovic N, Rabinowich H, Lee Y, Jost L, Herberman RB and Whiteside TL: Characteristics of human natural killer cells obtained by rapid IL2-induced adherence to plastic. Cell Immunol 151: 133-157, 1993.
11. Vujanovic N, Yasumura S, Hirabayashi H, Lin W-c, Watkins S, Herberman RB and Whiteside TL: Antitumor activities of subsets of human II2 activated natural killer cells in solid tissues. J Immunol 154: 281-289, 1994.
12. Yasumura S, Hirabayashi H, Schwanz DR, Tuso JF, Johnson JT, Herberman RB and Whiteside TL: Human cytotoxic T cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res 53: 1461-1468, 1993.
13. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside TL: Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49: 5167-5175, 1989.
14. Sacchi M, Snyderman CH, Heo DS, Johnson JT, D'Amico F, Herberman RB and Whiteside TL: Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Cancer Res 50: 3113-3118, 1990.
15. Whiteside TL, Bryant J, Day R and Herberman RB: Natural killer cytotoxicity in the diagnosis of immune dysfunction: Criteria for a reproducible assay. J Clin Lab Anal 4: 102-114, 1990.
16. Heo DS, Park J-G, Hata K, Day R, Herberman RB and Whiteside TL: Evaluation of tetrazolium-based semi-automatic colorimetric assay for measurement of antitumor cytotoxicity. Cancer Res 50: 3681-3690, 1990.
17. Matzinger P: The Jam test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 145: 185-192, 1991.
18. Friberg D, Bryant J, Shannon W and Whiteside TL: in vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation. Clin Diag Lab Immunol 1: 261-268, 1994.
19. Yasumura S, Weidman E, Hirabayashi H, Johnson JT, Herberman RB and Whiteside TL: HLA restriction and T-cell receptor Vβ gene expression of cytotoxic T lymphocytes reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 57: 297-305, 1994.
20. Vujanovic N, Nagashima S, Herberman RB, Whiteside TL: The nonsecretory killing pathway of natural killer cells. Nat Immunity 14: 73, 1995.
21. Sacchi M, Vitolo D, Sedelmayr P, Rabinowich H, Johnson JT, Herberman RB and Whiteside TL: Induction of tumor regression in experimental model of human head an neck cancer by human A-LAK cells and IL2: Int J Cancer 47: 784-791, 1991.